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Introduction 
Vitiligo is an acquired skin disorder clinically 
characterized by the development of depigmented 
macules and patches, caused by the selective 
autoimmune destruction of melanocytes [1]. At 
present, there is no definitive cure for this condition 
and existing treatment options are often inadequate. 
Although the exact pathogenesis of vitiligo remains 
only partially understood, it is believed that IFNγ 
signal transduction, as mediated through the 
canonical JAK-STAT (Janus kinase-signal transducers 
and activators of transcription) pathway, drives 
vitiligo autoimmunity, suggesting a potential 
therapeutic role for JAK inhibitors in the treatment of 
vitiligo [2, 3]. However, as with other novel targeted 
therapies, paradoxical cutaneous findings may be 
observed when alternative uninhibited pathways are 
upregulated, inflammatory cascades are altered, 
and/or cytokine balance is disrupted. Herein, we 
report a case of new-onset generalized vitiligo in a 
previously unaffected patient who had received oral 
tofacitinib therapy for rheumatoid arthritis. 
 
Case Report 
A 36-year-old woman with rheumatoid arthritis 
presented for evaluation of progressive 
Abstract 
With recent advancements in the understanding of 
vitiligo pathogenesis, Janus kinase (JAK) inhibitors 
have emerged as a promising new treatment 
modality, but their effects remain incompletely 
elucidated. Tofacitinib, an oral JAK 1/3 inhibitor 
approved for the treatment of rheumatoid arthritis, 
has previously been shown to induce significant re-
pigmentation in vitiligo. However, as with other 
novel targeted therapies, cutaneous adverse effects 
have been observed. We report a 36-year-old woman 
with a history of rheumatoid arthritis, refractory to 
multiple pharmacotherapies, who was initiated on 
tofacitinib and subsequently developed progressive 
depigmented patches consistent with new-onset 
vitiligo. Although definitive causation cannot be 
established in this case without additional studies, it 
is important to note that many targeted therapies 
have the potential to induce paradoxical effects, that 
is, the occurrence or exacerbation of pathologic 
conditions that have been shown to respond to these 
medications. Paradoxical findings with other 
targeted therapies include the occurrence of 
melanoma during treatment with BRAF inhibitors, 
keratoacanthomas with PD-1 inhibitors, vitiligo and 
psoriasis with TNF-alpha inhibitors, and hidradenitis 
suppurativa with various biologic agents. Although 
JAK inhibitors hold therapeutic promise in the 
treatment of inflammatory skin disorders, further 
research is warranted to more fully comprehend their 
effects. 
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depigmented patches that developed over the 
preceding four months. Diagnosed with rheumatoid 
arthritis two years prior to presentation, the patient 
had failed multiple disease-modifying antirheumatic 
drugs and tumor necrosis factor (TNF) inhibitors. 
Prior therapies included methotrexate, certolizumab 
pegol, golimumab, and infliximab. The patient also 
had a history of Grave hyperthyroidism with papillary 
thyroid microcarcinoma, for which she underwent 
total thyroidectomy prior to her diagnosis of 
rheumatoid arthritis, with euthyroid maintenance on 
levothyroxine. After experiencing an autoantibody-
mediated anaphylactic reaction to infliximab 
infusion, she was switched to monotherapy with 
tofacitinib citrate (extended-release 11mg daily) for 
rheumatoid arthritis. At her rheumatology clinic 
follow-up visit four months following initiation of 
tofacitinib she reported good efficacy of tofacitinib 
for her joint pain, along with the concurrent 
development of depigmented patches on her neck, 
chest, arms, and hands, for which she was referred for 
dermatology consultation (Figure 1). Routine 
laboratory tests, including complete blood count 
and comprehensive metabolic panel, were stable  
during her four-month treatment on tofacitinib, with 
an overall decrease in erythrocyte sedimentation 
rate from 41mm/hr to 26mm/hr. The diagnosis of 
generalized vitiligo was made based on clinical 
presentation and tofacitinib was immediately 
discontinued. The patient followed up in 
dermatology clinic six weeks (Figure 2), three 
months, and six months later without notable 
repigmentation or progression of vitiligo. 
Approximately 18 months later, she self-reported no 
change in the severity and extent of involvement of  
 
Figure 1. Development of vitiligo on the dorsal hands after four 
months of treatment with tofacitinib citrate extended-release 
11mg daily for rheumatoid arthritis.  
 
Figure 2. Persistence of vitiligo on the dorsal hands after six weeks 
following discontinuation of tofacitinib.  
B 
A 
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the vitiligo area (i.e., no improvement or worsening). 
No rechallenge with tofacitinib or therapy for vitiligo 
was attempted. At the 18-month time period, the 
patient was only using non-steroidal anti-
inflammatory drugs for her rheumatoid arthritis with 
good control. 
 
Discussion 
Tofacitinib was approved by the U.S. Food and Drug 
Administration in 2012 for the treatment of 
moderate-to-severe RA in adults who demonstrate 
an inadequate response to methotrexate [4]. The 
most commonly reported adverse effects in phase II 
and III clinical trials were diarrhea, nasopharyngitis, 
upper respiratory tract infection, and headache [5].  
The incidence of dermatologic reactions is not 
known, but rash, erythema, and pruritus have been 
reported [5]. Janus kinase inhibitors, including oral 
and topical tofacitinib, have emerged as well-
tolerated and variably effective treatment options 
for a wide spectrum of inflammatory skin conditions 
including atopic dermatitis, plaque psoriasis, 
alopecia areata, and vitiligo in case reports and 
ongoing clinical trials [2, 3, 6, 7]. 
Emerging research studies investigating the 
immunopathogenic pathway underlying vitiligo 
have facilitated the development of new, targeted 
pharmacologic therapies. It has been shown that the 
IFNγ/CXCL10 chemokine axis is required for the 
progression and maintenance of vitiligo. IFNγ signal 
transduction occurs through the JAK-STAT pathway 
Table 1. Paradoxical adverse effects of common targeted therapies used for dermatologic diseases. 
Targeted therapy 
class 
Agents within 
class Therapeutic Indications 
Paradoxical 
adverse 
effect(s) Reversibility 
BRAF inhibitors Dabrafenib 
Vemurafenib Melanoma 
Cutaneous 
melanoma 
-Increased risk is reversible 
-New malignancy is not 
reversible 
PD-1 inhibitors 
Cemiplimab 
Nivolumab 
Pembrolizumab 
Cervical cancer 
Colorectal cancer 
Cutaneous SCC 
Gastric cancer 
Head and neck SCC 
Hepatocellular carcinoma 
Hodgkin’s lymphoma 
Lung SCC 
Melanoma 
Merkel cell carcinoma 
NSCLC 
RCC 
Small cell lung cancer 
Urothelial carcinoma 
Cutaneous 
squamous cell 
carcinoma/kerat
oacanthoma 
- Increased risk is reversible 
- Some tumors have regressed
without treatment 
 
TNFα inhibitors 
Adalimumab 
Etanercept 
Infliximab 
Ankylosing spondylitis 
Crohn’s disease 
Hidradenitis suppurativa† 
Juvenile idiopathic arthritis 
Psoriasis 
Psoriatic arthritis 
Rheumatoid arthritis 
Ulcerative colitis 
Hidradenitis 
suppurativa  
- Yes, with treatment and d/c 
medication 
Psoriasis - Yes, with treatment and d/c medication 
JAK inhibitors 
Ruxolitinib 
Tofacitinib 
Myelofibrosis 
Polycythemia vera 
Psoriasis 
Rheumatoid arthritis 
Vitiligo† 
 - Unknown 
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and leads to CXCL10 expression in keratinocytes, 
ultimately resulting in the recruitment of 
autoreactive CD8+ cytotoxic T lymphocytes to the 
skin [8]. Activated cytotoxic T lymphocytes are 
believed to migrate to sites of inflammation, 
promote further T cell recruitment, and produce 
IFNγ, which inhibits melanogenesis and also directly 
induces melanocyte apoptosis, thereby driving 
vitiligo autoimmunity [9]. 
The findings of this translational research led 
Craiglow and King to pursue a therapeutic trial of 
oral tofacitinib citrate in a patient with generalized 
vitiligo who had failed conventional treatments. Five 
months of treatment resulted in near-complete 
repigmentation of her face and hands, with partial 
repigmentation of the remaining lesions [2]. The 
authors proposed that because IFNγ-induced 
CXCL10 mediates depigmentation, the use of 
tofacitinib as a JAK 1/3 inhibitor to block IFNγ 
signaling effectively attenuated CXCL10 secretion by 
keratinocytes and clinically resulted in 
repigmentation [2, 4]. Supporting this hypothesis are 
reports of significant clinical improvement in facial 
vitiligo in patients treated with topical or oral 
ruxolitinib, a JAK 1/2 inhibitor approved for use in 
myelodysplastic disorders [10, 11]. 
Cutaneous adverse effects that have been reported 
in association with JAK inhibitors include herpes 
zoster, disseminated molluscum, eruptive squamous 
cell carcinomas, drug reaction with eosinophilia and 
systemic symptoms, and morbilliform drug 
eruptions [12]. To our knowledge, new-onset vitiligo 
occurring during treatment with tofacitinib has not 
been previously reported in the literature. 
Arguments for causation cannot be validated in this 
isolated case, but the rapid development of de novo 
vitiligo shortly after initiation with tofacitinib is 
noteworthy, as topical and oral JAK inhibitors are 
currently being studied as a promising therapeutic 
modality for vitiligo. Although the medication may 
have served as a triggering factor, the association of 
vitiligo with other underlying autoimmune diseases, 
such as rheumatoid arthritis and thyroid disease, as 
in this patient, cannot be discounted. 
As there are complex interconnections between the 
JAK-STAT pathway and other cell signaling networks, 
there are multiple potential molecular mechanisms 
by which the onset of vitiligo could have been 
triggered in this case. Tofacitinib is a pan-JAK 
inhibitor with potent functional selectivity for JAK3- 
and JAK1-dependent STAT activation over JAK2-
mediated pathways [13]. We postulate that de novo 
development of generalized vitiligo in our patient 
may have been triggered by JAK 1/3 blockade 
causing a paradoxical upregulation of IFNγ signaling 
via JAK2. Additionally, JAK inhibition affects not only 
the IFNγ pathway, but also modulates the signal 
transmission and production of multiple pro-
inflammatory cytokines including IL1, IL4, IL7, IL9, 
IL15, and IL21 [14, 15]. It is unclear to what extent 
signaling by these other inflammatory cascades are 
abrogated by tofacitinib-induced JAK blockade. 
The use of several targeted therapies for the 
treatment of dermatologic conditions has resulted in 
the observation of immune-related and paradoxical 
adverse effects, the latter defined as the occurrence 
or exacerbation of pathologic conditions during 
treatment with an agent that should be effective for 
that disease. Following is a brief, non-exhaustive 
review of immune-related and paradoxical adverse 
effects that have been observed with the 
administration of these novel targeted therapies. 
Table 1 provides a non-comprehensive list of 
commonly used medications in dermatology and 
their paradoxical cutaneous toxicities. 
Melanoma with BRAF inhibitors 
The MAPK signaling pathway plays a key role in 
melanoma tumorigenesis with dysregulation 
occurring due to BRAF mutations. With mutations 
found in approximately 40-60% of cutaneous 
melanomas, BRAF inhibitors are first-line 
therapeutics for patients with BRAF V600-mutant 
metastatic melanoma [16]. Cutaneous adverse 
effects, including malignant neoplasms, are among 
the most frequently observed toxicities with the 
selective BRAF inhibitors vemurafenib and 
dabrafenib [16, 17]. The development of new 
primary melanomas with a wild-type BRAF genotype 
have been reported in patients receiving treatment 
with BRAF inhibitors, arising as new pigmented 
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lesions or rapidly evolving, pre-existing melanocytic 
lesions [18–23]. In one study, up to 21% of patients 
on vemurafenib exhibited changes in their pre-
existing pigmented nevi that were consistent with 
melanoma [22]. Though it is known that patients 
previously diagnosed with melanoma are at 
increased risk of developing subsequent new 
primary melanomas, their lifetime risk is generally 
estimated to be 2-10% [22]. It is believed that these 
new primary melanomas were dormant and clinically 
undetectable before the initiation of BRAF inhibitor 
therapy; they then became clinically relevant by the 
paradoxical BRAF activation of wild-type cells. 
Preclinical studies suggest that exposure to selective 
V600E BRAF blockers promotes the proliferation of 
BRAF wild-type melanocytes through paradoxical 
activation of the MAPK pathway, causing 
upregulation of cyclin D1 (required for cell cycle 
progression) and resulting in proliferative skin 
toxicities including oncogenesis [24, 25]. 
Keratoacanthomas with PD-1 inhibitors 
Used to treat unresectable or metastatic melanoma, 
pembrolizumab is an immune checkpoint inhibitor 
targeting the programmed cell death 1 (PD-1) 
receptor of lymphocytes. The eruption of 
keratoacanthomas (KAs) has been reported in 
patients receiving pembrolizumab [26, 27]. More 
recently, pembrolizumab has demonstrated efficacy 
in the treatment of locally advanced squamous cell 
carcinomas [28]. One proposed mechanism for the 
occurrence of new-onset keratoacanthomas in 
patients receiving anti-PD-1 therapy is that the 
resultant enhanced immune response could induce 
epithelial proliferation and chronic inflammation, 
which has been shown to be a driver of squamous 
cell carcinoma development [26, 27]. Furthermore, it 
has recently been shown that a homo- or 
heterozygous deletion of PD-1 permits uncontrolled 
T cell proliferation with oncogenically-activated T 
cell receptor pathways in vivo, suggesting a 
mechanism for oncogenesis with anti-PD-1 therapy 
[29]. 
Vitiligo with PD-1 inhibitors 
Other immune-driven cutaneous phenomena have 
also been observed with anti-PD-1 therapy, such as 
with pembrolizumab and nivolumab [30]. Although 
this is not a paradoxical reaction, it was included for 
completeness as it is an example of drug-induced 
vitiligo with a potentially distinct mechanism from 
the autoimmune variety. Vitiligo is a classic side 
effect of PD-1 inhibitors, as it has been suggested 
that melanocytic antigens are released by tumor 
cells when destroyed by PD-1 antibodies, which 
induces an immune response against native 
melanocytes as well [31]. However, these treatment-
associated lesions display a clinical and biological 
pattern different from spontaneous vitiligo, with the 
anti-PD-1 induced vitiligo-like lesions characterized 
by multiple flecked, depigmented macules evolving 
toward larger plaques, without evidence of 
Koebnerization [32]. The immunophenotype of 
these vitiligo-like lesions is also different from 
spontaneous vitiligo. Larsabal et al. found a unique 
CXCR3+ CD8 T cell-predominant infiltrate in 
perilesional biopsies of patients with vitiligo-like 
lesions receiving anti-PD-1 therapy for metastatic 
melanoma or lung cancer [32]. They also detected 
increased serum levels of CXCL10 and the expression 
of IFNγ and TNFα by skin-infiltrating CD8 T cells, not 
found in patients with spontaneous vitiligo or 
healthy controls [32]. These findings suggest a 
pathophysiological mechanism of depigmentation 
distinct from vitiligo through an immune-mediated 
side effect of anti-PD1 therapy. 
Vitiligo with TNF inhibitors 
Anti-TNF agents have been utilized as an off-label 
treatment option for vitiligo, but their administration 
has also been associated with the emergence or 
worsening of vitiligo [33, 34]. Abnormal expression 
of the pro-inflammatory cytokine TNF has been 
detected in active vitiligo lesions, making TNF a 
potential therapeutic target. Stabilization of disease 
and repigmentation have been achieved with TNF 
inhibition in patients with progressive vitiligo. 
However, paradoxically, treatment can be associated 
with de novo vitiligo development when anti-TNF 
agents are used for other chronic inflammatory 
conditions [35–37]. In one population-based cohort 
study, a significantly increased risk of vitiligo was 
observed in individuals who were treated with TNF 
inhibitors for ankylosing spondylitis, Crohn disease, 
or ulcerative colitis compared to those who were 
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unexposed [37]. Thus, TNF has dual properties in the 
skin, giving rise to cytokine imbalance and 
heterogeneous clinical effects with its blockade. 
Psoriasis with TNF inhibitors 
Shown to be both induced by, and treated with TNF 
inhibitors, psoriasis is a classic example of a 
paradoxical adverse effects of a common biologic 
agent. Anti-TNF agents have been associated with 
the induction of psoriasis and psoriasiform eruptions 
in patients being treated for rheumatologic or 
inflammatory bowel diseases, as well as with 
exacerbation of existing psoriatic disease, the latter 
characterized by possible new areas of localization 
and distinct morphology [38–42]. A subset of 
affected patients exhibits new psoriatic lesions upon 
switching to an alternative TNF inhibitor as well [39, 
43]. This phenomenon may be partly explained by a 
cytokine imbalance from TNF blockade, including 
overexpression of IFNγ and IFNα by plasmacytoid 
dendritic cells, which in turn drive the development 
of psoriatic lesions in genetically predisposed 
patients [38, 44]. 
Hidradenitis suppurativa with multiple biologic 
agents 
New onset hidradenitis suppurativa has been 
reported during administration of TNF inhibitors, 
rituximab, and tocilizumab for chronic inflammatory 
diseases and complete resolution has been observed 
after treatment discontinuation or transition to 
another biologic agent [43, 45, 46]. Drug rechallenge 
may cause hidradenitis relapse in some patients [45]. 
Possible hypotheses for the occurrence of 
hidradenitis as a paradoxical adverse effects of TNF 
inhibitor or other biologic therapy include local 
modification of cytokine balance, activation of 
alternate pathways such as type I IFN or IL1β, and/or 
an increased risk of infection triggering hidradenitis 
suppurativa [43]. 
 
Conclusion 
New immunotherapies are revolutionizing the 
clinical management of various dermatologic 
diseases. Patients receiving these novel agents may 
experience paradoxical development of the same 
pathologic conditions that these drugs have been 
shown to treat. The JAK 1/3 inhibitor tofacitinib has 
emerged as a potential therapeutic strategy for 
vitiligo, but our case documents de novo vitiligo 
arising in a patient with rheumatoid arthritis treated 
with oral tofacitinib. Although a paradoxical effect of 
tofacitinib cannot be definitively confirmed in this 
case without additional evidence from case series 
and randomized controlled trials, we propose that 
this de novo vitiligo may have resulted from 
paradoxical upregulation of IFNγ signaling through 
JAK 2. Vitiligo is typically asymptomatic but has 
significant aesthetic and psychosocial associations. 
However, the clinical benefits of tofacitinib for the 
treatment of rheumatoid arthritis and other 
conditions may very well still outweigh the potential 
risks of a paradoxical reaction. 
As advances in our understanding of the molecular 
mechanisms of disease result in new, targeted 
therapies, clinician awareness and recognition of 
immune-mediated and paradoxical adverse effects 
are critical for informed clinical decision-making and 
patient counseling. Although very promising for the 
treatment of vitiligo and other immune-mediated 
dermatoses, JAK inhibitors require further 
investigation to assess the side effect profile. 
Prospective, long-term safety evaluations of novel 
JAK inhibitors such as tofacitinib are warranted as the 
potential therapeutic applications continue to 
expand. 
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